Article Text
PDFEditorial
Sudden cardiac death: opportunities for prevention
Abstract
The evidence base for implantable cardioverter-defibrillator (ICD) therapy requires expansion of guidance/indications to allow UK physicians to treat a broader range of patients. The ICD clinical consultees to the National Institute for Health and Clinical Excellence (NICE) review current guidance/guidelines, explain the evidence base, and suggest a UK ICD implantation strategy
- ATP, antitachycardia pacing
- AVID, antiarrhythmics versus implantable defibrillators study
- CABG Patch, coronary artery bypass graft patch trial
- CARE-HF, cardiac resynchronization-heart failure study
- CASH, cardiac arrest study Hamburg
- CIDS, Canadian implantable defibrillator study
- CRT, cardiac resynchronisation therapy
- DAVID, dual chamber and VVI implantable defibrillator trial
- DINAMIT, defibrillator in acute myocardial infarction trial
- EF, ejection fraction
- EPS, electrophysiological study
- ICD, implantable cardioverter-defibrillator
- MADIT I, multicenter automatic defibrillator implantation trial
- MADIT II, multicenter automatic defibrillator implantation trial II
- MI, myocardial infarction
- MUSTT, multicenter unsustained tachycardia trial
- NHS, National Health Service
- NICE, National Institute for Health and Clinical Excellence
- NYHA, New York Heart Association
- QoL, quality of life
- SCD, sudden cardiac death
- SCD HeFT, sudden cardiac death in heart failure trial
- VF, ventricular fibrillation
- VT, ventricular tachycardia
- cost efficacy
- implantable cardioverter-defibrillator
- ICD
- guidelines
- sudden cardiac death